Antisoma Inc.

161 articles about Antisoma Inc.

• Antisoma PLC's Preliminary Results For The Year Ended 30 June 2009

  9/14/2009

• Antisoma PLC to present at the Rodman & Renshaw Healthcare Conference in New York

  9/3/2009

• Antisoma PLC: Phase III Trial Of ASA404 In Lung Cancer Completes Patient Enrollment

  9/1/2009

• Antisoma PLC and Bryan Oncor, Inc. Announce Deal for Anti-Cancer Drug P2045

  8/11/2009

• Antisoma PLC Announces Discontinuation of Development of AS1402

  8/10/2009

• Antisoma PLC to present at the Canaccord Adams 29th Annual Global Growth Conference in Boston

  8/5/2009

• Antisoma PLC to Present at Piper Jaffray Europe Conference in London

  6/18/2009

• Antisoma PLC to present at 3rd Annual Jefferies Healthcare Conference in New York

  6/15/2009

• Antisoma PLC to Present at 8th Annual Needham Life Sciences Conference in New York

  6/5/2009

• Antisoma PLC's AS1409 Shows Anti-Cancer Activity In Phase I Trial

  6/1/2009

• Antisoma PLC To Advance AS1411 In AML Based On Positive Phase II Data Presented At American Society of Clinical Oncology

  5/29/2009

• Antisoma PLC: Phase II Trial Of ASA404 Published In Lung Cancer

  5/21/2009

• Antisoma PLC Sells Oral Fludarabine to Sanofi-Aventis (Massachusetts) for $65 Million

  5/12/2009

• Antisoma PLC Interim Management Statement

  5/7/2009

• Data on Three Antisoma PLC Drugs Presented at American Association for Cancer Research Meeting

  4/20/2009

• Antisoma PLC: Phase III Development Of ASA404 In Lung Cancer Extended To Japan

  3/25/2009

• Antisoma PLC Reports Half-Year Results For The Six Months To 31 December 2008

  2/17/2009

• Antisoma PLC's ASA404 To Be Developed In Breast Cancer

  2/12/2009

• Antisoma PLC to Present at 11th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York

  2/3/2009

• Antisoma PLC Release: ASA404 Enters Pivotal Phase III Trial In Second-Line Lung Cancer

  1/13/2009